{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:08:17Z","timestamp":1783966097552,"version":"3.55.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21wm0425007"],"award-info":[{"award-number":["JP21wm0425007"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21wm0425017"],"award-info":[{"award-number":["JP21wm0425017"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25wm0625518"],"award-info":[{"award-number":["JP25wm0625518"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ak0101215"],"award-info":[{"award-number":["JP23ak0101215"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ak0101221"],"award-info":[{"award-number":["JP24ak0101221"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22gm1410011"],"award-info":[{"award-number":["JP22gm1410011"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24zf0127011"],"award-info":[{"award-number":["JP24zf0127011"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23gm1910005"],"award-info":[{"award-number":["JP23gm1910005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23H02669"],"award-info":[{"award-number":["JP23H02669"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K19425"],"award-info":[{"award-number":["JP23K19425"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K18365"],"award-info":[{"award-number":["JP24K18365"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SRF, Toyoaki Scholarship Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41380-026-03567-7","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:44:25Z","timestamp":1775076265000},"page":"4589-4601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia"],"prefix":"10.1038","volume":"31","author":[{"given":"Rinako","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisa","family":"Fukuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Sawahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9072-2546","authenticated-orcid":false,"given":"Daisuke","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-4041","authenticated-orcid":false,"given":"Akihiro","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayoshi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3705-5473","authenticated-orcid":false,"given":"Tetsuo","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-7748","authenticated-orcid":false,"given":"Taku","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kaibuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-4898","authenticated-orcid":false,"given":"Norio","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-4184","authenticated-orcid":false,"given":"Hiroyuki","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-5180","authenticated-orcid":false,"given":"Kiyofumi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"3567_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrd.2016.28","volume":"15","author":"MJ Millan","year":"2016","unstructured":"Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15:485\u2013515.","journal-title":"Nat Rev Drug Discov"},{"key":"3567_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399:473\u201386.","journal-title":"Lancet"},{"key":"3567_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01904-2","volume":"12","author":"DL Spark","year":"2022","unstructured":"Spark DL, Fornito A, Langmead CJ, Stewart GD. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry. 2022;12:147.","journal-title":"Transl Psychiatry"},{"key":"3567_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ddr.21337","volume":"77","author":"NP Maric","year":"2016","unstructured":"Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving current treatments for schizophrenia. Drug Dev Res. 2016;77:357\u201367.","journal-title":"Drug Dev Res"},{"key":"3567_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"3567_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/molecules23082087","volume":"23","author":"P Stepnicki","year":"2018","unstructured":"Stepnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23:2087.","journal-title":"Molecules"},{"key":"3567_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","volume":"132","author":"MC Lobo","year":"2022","unstructured":"Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324\u201361.","journal-title":"Neurosci Biobehav Rev"},{"key":"3567_CR8","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28:1902\u201318.","journal-title":"Mol Psychiatry"},{"key":"3567_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789\u201396.","journal-title":"Arch Gen Psychiatry"},{"key":"3567_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJM199709183371202","volume":"337","author":"R Rosenheck","year":"1997","unstructured":"Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. N Engl J Med. 1997;337:809\u201315.","journal-title":"N Engl J Med"},{"key":"3567_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0706743717718167","volume":"62","author":"D Siskind","year":"2017","unstructured":"Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62:772\u20137.","journal-title":"Can J Psychiatry"},{"key":"3567_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JCP.0000000000001329","volume":"41","author":"G Blackman","year":"2021","unstructured":"Blackman G, Lisshammar JEL, Zafar R, Pollak TA, Pritchard M, Cullen AE, et al. Clozapine response in schizophrenia and hematological changes. J Clin Psychopharmacol. 2021;41:19\u201324.","journal-title":"J Clin Psychopharmacol"},{"key":"3567_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/070674371405900206","volume":"59","author":"H Li","year":"2014","unstructured":"Li H, Lu Q, Xiao E, Li Q, He Z, Mei X. Methamphetamine enhances the development of schizophrenia in first-degree relatives of patients with schizophrenia. Can J Psychiatry. 2014;59:107\u201313.","journal-title":"Can J Psychiatry"},{"key":"3567_CR14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","volume":"604","author":"V Trubetskoy","year":"2022","unstructured":"Trubetskoy V, Pardi\u00f1as AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604:502\u20138.","journal-title":"Nature"},{"key":"3567_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00917-z","volume":"10","author":"M Sekiguchi","year":"2020","unstructured":"Sekiguchi M, Sobue A, Kushima I, Wang C, Arioka Y, Kato H, et al. ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk. Transl Psychiatry. 2020;10:247.","journal-title":"Transl Psychiatry"},{"key":"3567_CR16","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3390\/cells10071831","volume":"10","author":"N Mosaddeghzadeh","year":"2021","unstructured":"Mosaddeghzadeh N, Ahmadian MR. The RHO family GTPases: mechanisms of regulation and signaling. Cells. 2021;10:1831.","journal-title":"Cells"},{"key":"3567_CR17","doi-asserted-by":"publisher","first-page":"11507","DOI":"10.2147\/OTT.S222564","volume":"12","author":"L Liu","year":"2019","unstructured":"Liu L, Xie D, Xie H, Huang W, Zhang J, Jin W, et al. ARHGAP10 inhibits the proliferation and metastasis of CRC cells via blocking the activity of RhoA\/AKT signaling pathway. Onco Targets Ther. 2019;12:11507\u201316.","journal-title":"Onco Targets Ther"},{"key":"3567_CR18","doi-asserted-by":"publisher","first-page":"15623","DOI":"10.3390\/ijms242115623","volume":"24","author":"R Tanaka","year":"2023","unstructured":"Tanaka R, Yamada K. Genomic and reverse translational analysis discloses a role for small GTPase RhoA signaling in the pathogenesis of schizophrenia: Rho-Kinase as a novel drug target. Int J Mol Sci. 2023;24:15623.","journal-title":"Int J Mol Sci"},{"key":"3567_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106589","volume":"187","author":"R Tanaka","year":"2023","unstructured":"Tanaka R, Liao J, Hada K, Mori D, Nagai T, Matsuzaki T, et al. Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene. Pharmacol Res. 2023;187:106589.","journal-title":"Pharmacol Res"},{"key":"3567_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-021-00735-4","volume":"14","author":"K Hada","year":"2021","unstructured":"Hada K, Wulaer B, Nagai T, Itoh N, Sawahata M, Sobue A, et al. Mice carrying a schizophrenia-associated mutation of the Arhgap10 gene are vulnerable to the effects of methamphetamine treatment on cognitive function: association with morphological abnormalities in striatal neurons. Mol Brain. 2021;14:21.","journal-title":"Mol Brain"},{"key":"3567_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106838","volume":"194","author":"J Liao","year":"2023","unstructured":"Liao J, Dong G, Zhu W, Wulaer B, Mizoguchi H, Sawahata M, et al. Rho kinase inhibitors ameliorate cognitive impairment in a male mouse model of methamphetamine-induced schizophrenia. Pharmacol Res. 2023;194:106838.","journal-title":"Pharmacol Res"},{"key":"3567_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175207","volume":"931","author":"S Takase","year":"2022","unstructured":"Takase S, Liao J, Liu Y, Tanaka R, Miyagawa Y, Sawahata M, et al. Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia. Eur J Pharmacol. 2022;931:175207.","journal-title":"Eur J Pharmacol"},{"key":"3567_CR23","doi-asserted-by":"publisher","first-page":"e29846","DOI":"10.4161\/sgtp.29846","volume":"5","author":"L Julian","year":"2014","unstructured":"Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846.","journal-title":"Small GTPases"},{"key":"3567_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acn3.19","volume":"1","author":"JH Lee","year":"2014","unstructured":"Lee JH, Zheng Y, von, Bornstadt D, Wei Y, Balcioglu A, et al. Selective ROCK2 inhibition in focal cerebral ischemia. Ann Clin Transl Neurol. 2014;1:2\u201314.","journal-title":"Ann Clin Transl Neurol"},{"key":"3567_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0014-5793(96)00811-3","volume":"392","author":"O Nakagawa","year":"1996","unstructured":"Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine\/threonine kinase in mice. FEBS Lett. 1996;392:189\u201393.","journal-title":"FEBS Lett"},{"key":"3567_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/FJC.0b013e3182a3718f","volume":"62","author":"J Shi","year":"2013","unstructured":"Shi J, Wei L. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol. 2013;62:341\u201354.","journal-title":"J Cardiovasc Pharmacol"},{"key":"3567_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrcardio.2010.136","volume":"7","author":"G Loirand","year":"2010","unstructured":"Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol. 2010;7:637\u201347.","journal-title":"Nat Rev Cardiol"},{"key":"3567_CR28","volume":"70","author":"F Ali","year":"2022","unstructured":"Ali F, Ilyas A. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease. Curr Res Transl Med. 2022;70:103343.","journal-title":"Curr Res Transl Med"},{"key":"3567_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"3567_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31390-w","volume":"8","author":"A Sobue","year":"2018","unstructured":"Sobue A, Kushima I, Nagai T, Shan W, Kohno T, Aleksic B, et al. Genetic and animal model analyses reveal the pathogenic role of a novel deletion of RELN in schizophrenia. Sci Rep. 2018;8:13046.","journal-title":"Sci Rep"},{"key":"3567_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.pbb.2010.04.027","volume":"96","author":"Y Ohno","year":"2010","unstructured":"Ohno Y, Okano M, Imaki J, Tatara A, Okumura T, Shimizu S. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. Pharmacol Biochem Behav. 2010;96:175\u201380.","journal-title":"Pharmacol Biochem Behav"},{"key":"3567_CR32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204835119","volume":"119","author":"TI Kam","year":"2022","unstructured":"Kam TI, Park H, Chou SC, Van Vranken JG, Mittenbuhler MJ, Kim H, et al. Amelioration of pathologic alpha-synuclein-induced parkinson\u2019s disease by irisin. Proc Natl Acad Sci USA. 2022;119:e2204835119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3567_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/neu.2021.33","volume":"34","author":"B Kaygisiz","year":"2022","unstructured":"Kaygisiz B, Aydin S, Yildirim E, Musmul A, Erol K, Kilic FS. The effects of galangin in prepulse inhibition test and experimental schizophrenia models. Acta Neuropsychiatr. 2022;34:37\u201346.","journal-title":"Acta Neuropsychiatr"},{"key":"3567_CR34","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1016\/j.cell.2023.10.014","volume":"186","author":"P Shang","year":"2023","unstructured":"Shang P, Rong N, Jiang JJ, Cheng J, Zhang MH, Kang D, et al. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. Cell. 2023;186:5347\u201362 e5324.","journal-title":"Cell"},{"key":"3567_CR35","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/bph.16093","volume":"180","author":"H Kubota","year":"2023","unstructured":"Kubota H, Kunisawa K, Wulaer B, Hasegawa M, Kurahashi H, Sakata T, et al. High salt induces cognitive impairment via the interaction of the angiotensin II-AT(1) and prostaglandin E2-EP(1) systems. Br J Pharmacol. 2023;180:2393\u2013411.","journal-title":"Br J Pharmacol"},{"key":"3567_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1042\/BJ20121070","volume":"449","author":"MK Stewart","year":"2013","unstructured":"Stewart MK, Gong XQ, Barr KJ, Bai D, Fishman GI, Laird DW. The severity of mammary gland developmental defects is linked to the overall functional status of Cx43 as revealed by genetically modified mice. Biochem J. 2013;449:401\u201313.","journal-title":"Biochem J"},{"key":"3567_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0306-4530(87)90006-0","volume":"12","author":"DG Morgan","year":"1987","unstructured":"Morgan DG, Randall JS, Telford NA, Gordon MN, Sinha YN, Finch CE, et al. Genotypic influences on pituitary responsiveness to haloperidol in mice. Psychoneuroendocrinology. 1987;12:211\u20138.","journal-title":"Psychoneuroendocrinology"},{"key":"3567_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/schbul\/sbn104","volume":"36","author":"YE Savoy","year":"2010","unstructured":"Savoy YE, Ashton MA, Miller MW, Nedza FM, Spracklin DK, Hawthorn MH, et al. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. Schizophr Bull. 2010;36:410\u20138.","journal-title":"Schizophr Bull"},{"key":"3567_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.abb.2011.01.018","volume":"510","author":"ME Grassie","year":"2011","unstructured":"Grassie ME, Moffat LD, Walsh MP, MacDonald JA. The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1delta. Arch Biochem Biophys. 2011;510:147\u201359.","journal-title":"Arch Biochem Biophys"},{"key":"3567_CR40","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3389\/fphys.2020.00701","volume":"11","author":"MD \u00c1lvarez-Santos","year":"2020","unstructured":"\u00c1lvarez-Santos MD, \u00c1lvarez-Gonz\u00e1lez M, Estrada-Soto S, Baz\u00e1n-Perkins B. Regulation of myosin light-chain phosphatase activity to generate airway smooth muscle hypercontractility. Front Physiol. 2020;11:701.","journal-title":"Front Physiol"},{"key":"3567_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/BF00216006","volume":"91","author":"JA Lieberman","year":"1987","unstructured":"Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987;91:415\u201333.","journal-title":"Psychopharmacology (Berl)"},{"key":"3567_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1192\/bjp.185.3.196","volume":"185","author":"C Curran","year":"2004","unstructured":"Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196\u2013204.","journal-title":"Br J Psychiatry"},{"key":"3567_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12272-017-0897-y","volume":"40","author":"EJ Shin","year":"2017","unstructured":"Shin EJ, Dang DK, Tran TV, Tran HQ, Jeong JH, Nah SY, et al. Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Arch Pharm Res. 2017;40:403\u201328.","journal-title":"Arch Pharm Res"},{"key":"3567_CR44","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.neubiorev.2008.03.012","volume":"32","author":"V Buben\u00edkov\u00e1-Valesov\u00e1","year":"2008","unstructured":"Buben\u00edkov\u00e1-Valesov\u00e1 V, Hor\u00e1cek J, Vrajov\u00e1 M, H\u00f6schl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008;32:1014\u201323.","journal-title":"Neurosci Biobehav Rev"},{"key":"3567_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1176\/appi.ajp.2014.13121691","volume":"172","author":"DC Javitt","year":"2015","unstructured":"Javitt DC, Freedman R. Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry. 2015;172:17\u201331.","journal-title":"Am J Psychiatry"},{"key":"3567_CR46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1592\/phco.29.1.64","volume":"29","author":"JR Bostwick","year":"2009","unstructured":"Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29:64\u201373.","journal-title":"Pharmacotherapy"},{"key":"3567_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/brain\/awz344","volume":"143","author":"M Bologna","year":"2020","unstructured":"Bologna M, Paparella G, Fasano A, Hallett M, Berardelli A. Evolving concepts on bradykinesia. Brain. 2020;143:727\u201350.","journal-title":"Brain"},{"key":"3567_CR48","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","volume":"59","author":"JW Newcomer","year":"2002","unstructured":"Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337\u201345.","journal-title":"Arch Gen Psychiatry"},{"key":"3567_CR49","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fphar.2015.00276","volume":"6","author":"S Hartmann","year":"2015","unstructured":"Hartmann S, Ridley AJ, Lutz S. The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease. Front Pharmacol. 2015;6:276.","journal-title":"Front Pharmacol"},{"key":"3567_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1042\/BJ20040344","volume":"384","author":"JD Doran","year":"2004","unstructured":"Doran JD, Liu X, Taslimi P, Saadat A, Fox T. New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem J. 2004;384:255\u201362.","journal-title":"Biochem J"},{"key":"3567_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1247\/csf.12018","volume":"37","author":"M Iizuka","year":"2012","unstructured":"Iizuka M, Kimura K, Wang S, Kato K, Amano M, Kaibuchi K, et al. Distinct distribution and localization of Rho-kinase in mouse epithelial, muscle and neural tissues. Cell Struct Funct. 2012;37:155\u201375.","journal-title":"Cell Struct Funct"},{"key":"3567_CR52","doi-asserted-by":"publisher","first-page":"e0177332","DOI":"10.1371\/journal.pone.0177332","volume":"12","author":"B Niego","year":"2017","unstructured":"Niego B, Lee N, Larsson P, De Silva TM, Au AEL, McCutcheon F, et al. Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin. PLOS One. 2017;12:e0177332.","journal-title":"PLOS One"},{"key":"3567_CR53","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/jcm9051328","volume":"9","author":"TM Seccia","year":"2020","unstructured":"Seccia TM, Rigato M, Ravarotto V, Calo LA. ROCK (RhoA\/Rho Kinase) in cardiovascular-renal pathophysiology: a review of new advancements. J Clin Med. 2020;9:1328.","journal-title":"J Clin Med"},{"key":"3567_CR54","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1212\/01.wnl.0000259588.97409.8f","volume":"68","author":"EE Benarroch","year":"2007","unstructured":"Benarroch EE. Rho GTPases: role in dendrite and axonal growth, mental retardation, and axonal regeneration. Neurology. 2007;68:1315\u20138.","journal-title":"Neurology"},{"key":"3567_CR55","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/cells9091972","volume":"9","author":"T Sarowar","year":"2020","unstructured":"Sarowar T, Grabrucker AM. Rho GTPases in the amygdala-a switch for fears? Cells. 2020;9:1972.","journal-title":"Cells"},{"key":"3567_CR56","doi-asserted-by":"publisher","first-page":"e24149","DOI":"10.1371\/journal.pone.0024149","volume":"6","author":"JL Hodges","year":"2011","unstructured":"Hodges JL, Newell-Litwa K, Asmussen H, Vicente-Manzanares M, Horwitz AR. Myosin IIb activity and phosphorylation status determines dendritic spine and post-synaptic density morphology. PLoS One. 2011;6:e24149.","journal-title":"PLoS One"},{"key":"3567_CR57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neuroscience.2012.04.044","volume":"251","author":"JR Glausier","year":"2013","unstructured":"Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90\u2013107.","journal-title":"Neuroscience"},{"key":"3567_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0920-9964(02)00201-3","volume":"58","author":"K Broadbelt","year":"2002","unstructured":"Broadbelt K, Byne W, Jones LB. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr Res. 2002;58:75\u201381.","journal-title":"Schizophr Res"},{"key":"3567_CR59","doi-asserted-by":"publisher","first-page":"535","DOI":"10.24272\/j.issn.2095-8137.2024.055","volume":"45","author":"L Yu","year":"2024","unstructured":"Yu L, Zeng F, Fan M, Zhang K, Duan J, Tan Y, et al. PCDH17 restricts dendritic spine morphogenesis by regulating ROCK2-dependent control of the actin cytoskeleton, modulating emotional behavior. Zool Res. 2024;45:535\u201350.","journal-title":"Zool Res"},{"key":"3567_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2022.100249","volume":"29","author":"PD Harvey","year":"2022","unstructured":"Harvey PD, Bosia M, Cavallaro R, Howes OD, Kahn RS, Leucht S, et al. Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art. Schizophr Res Cogn. 2022;29:100249.","journal-title":"Schizophr Res Cogn"},{"key":"3567_CR61","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11065-018-9388-2","volume":"28","author":"JM Sheffield","year":"2018","unstructured":"Sheffield JM, Karcher NR, Barch DM. Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev. 2018;28:509\u201333.","journal-title":"Neuropsychol Rev"},{"key":"3567_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.schres.2012.12.013","volume":"144","author":"E Bora","year":"2013","unstructured":"Bora E, Pantelis C. Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. Schizophr Res. 2013;144:31\u201336.","journal-title":"Schizophr Res"},{"key":"3567_CR63","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/schbul\/sbu198","volume":"41","author":"E Bora","year":"2015","unstructured":"Bora E, Pantelis C. Meta-analysis of cognitive impairment in first-episode bipolar disorder: comparison with first-episode schizophrenia and healthy controls. Schizophr Bull. 2015;41:1095\u2013104.","journal-title":"Schizophr Bull"},{"key":"3567_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/schbul\/sbr133","volume":"38","author":"A Adell","year":"2012","unstructured":"Adell A, Jim\u00e9nez-S\u00e1nchez L, L\u00f3pez-Gil X, Rom\u00f3n T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophr Bull. 2012;38:9\u201314.","journal-title":"Schizophr Bull"},{"key":"3567_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/srep14613","volume":"5","author":"J Nithianantharajah","year":"2015","unstructured":"Nithianantharajah J, McKechanie AG, Stewart TJ, Johnstone M, Blackwood DH, St Clair D, et al. Bridging the translational divide: identical cognitive touchscreen testing in mice and humans carrying mutations in a disease-relevant homologous gene. Sci Rep. 2015;5:14613.","journal-title":"Sci Rep"},{"key":"3567_CR66","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nn.3457","volume":"16","author":"JL Brigman","year":"2013","unstructured":"Brigman JL, Daut RA, Wright T, Gunduz-Cinar O, Graybeal C, Davis MI, et al. GluN2B in corticostriatal circuits governs choice learning and choice shifting. Nat Neurosci. 2013;16:1101\u201310.","journal-title":"Nat Neurosci"},{"key":"3567_CR67","doi-asserted-by":"publisher","first-page":"E7138","DOI":"10.1073\/pnas.1511670112","volume":"112","author":"DS Wheeler","year":"2015","unstructured":"Wheeler DS, Underhill SM, Stolz DB, Murdoch GH, Thiels E, Romero G, et al. Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine. Proc Natl Acad Sci USA. 2015;112:E7138\u20137147.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3567_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105832","volume":"173","author":"M Sawahata","year":"2021","unstructured":"Sawahata M, Asano H, Nagai T, Ito N, Kohno T, Nabeshima T, et al. Microinjection of reelin into the mPFC prevents MK-801-induced recognition memory impairment in mice. Pharmacol Res. 2021;173:105832.","journal-title":"Pharmacol Res"},{"key":"3567_CR69","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/schbul\/sbad098","volume":"49","author":"SB Powell","year":"2023","unstructured":"Powell SB, Swerdlow NR. The relevance of animal models of social isolation and social motivation for understanding schizophrenia: review and future directions. Schizophr Bull. 2023;49:1112\u201326.","journal-title":"Schizophr Bull"},{"key":"3567_CR70","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1038\/s41380-024-02540-6","volume":"29","author":"DC Li","year":"2024","unstructured":"Li DC, Hinton EA, Guo J, Knight KA, Sequeira MK, Wynne ME, et al. Social experience in adolescence shapes prefrontal cortex structure and function in adulthood. Mol Psychiatry. 2024;29:2787\u201398.","journal-title":"Mol Psychiatry"},{"key":"3567_CR71","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1523\/JNEUROSCI.21-04-01413.2001","volume":"21","author":"V Sandoval","year":"2001","unstructured":"Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001;21:1413\u20139.","journal-title":"J Neurosci"},{"key":"3567_CR72","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1471-4159.2007.05142.x","volume":"105","author":"A Fukakusa","year":"2008","unstructured":"Fukakusa A, Nagai T, Mizoguchi H, Otsuka N, Kimura H, Kamei H, et al. Role of tissue plasminogen activator in the sensitization of methamphetamine-induced dopamine release in the nucleus accumbens. J Neurochem. 2008;105:436\u201344.","journal-title":"J Neurochem"},{"key":"3567_CR73","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0168-0102(87)90044-7","volume":"4","author":"M Hara","year":"1987","unstructured":"Hara M, Akaike A, Sasa M, Takaori S. Acute effects of methamphetamine applied microiontophoretically to nucleus accumbens neurons in rats. Neurosci Res. 1987;4:279\u201390.","journal-title":"Neurosci Res"},{"key":"3567_CR74","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.npp.1300678","volume":"30","author":"EH Chartoff","year":"2005","unstructured":"Chartoff EH, Heusner CL, Palmiter RD. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology. 2005;30:1324\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"3567_CR75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1098-2396(199610)24:2<135::AID-SYN5>3.0.CO;2-G","volume":"24","author":"JP Druhan","year":"1996","unstructured":"Druhan JP, Rajabi H, Stewart J. MK-801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens. Synapse. 1996;24:135\u201346.","journal-title":"Synapse"},{"key":"3567_CR76","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jgh.12360","volume":"29","author":"T Fukuda","year":"2014","unstructured":"Fukuda T, Narahara Y, Kanazawa H, Matsushita Y, Kidokoro H, Itokawa N, et al. Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis. J Gastroenterol Hepatol. 2014;29:325\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"3567_CR77","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000852","volume":"3","author":"G Andre","year":"2014","unstructured":"Andre G, Sandoval JE, Retailleau K, Loufrani L, Toumaniantz G, Offermanns S, et al. Smooth muscle specific Rac1 deficiency induces hypertension by preventing p116RIP3-dependent RhoA inhibition. J Am Heart Assoc. 2014;3:e000852.","journal-title":"J Am Heart Assoc"},{"key":"3567_CR78","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Rezurock: multi-discipline review. July 16, 2021. Application number: 214783Orig1s000. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214783Orig1s000MultidisciplineR.pdf. Accessed June 24, 2024."},{"key":"3567_CR79","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.","journal-title":"Biomed Res Int"},{"key":"3567_CR80","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejphar.2018.12.003","volume":"844","author":"R Singh","year":"2019","unstructured":"Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol. 2019;844:231\u201340.","journal-title":"Eur J Pharmacol"},{"key":"3567_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13347","volume":"35","author":"M Fonseca","year":"2023","unstructured":"Fonseca M, Carmo F, Martel F. Metabolic effects of atypical antipsychotics: molecular targets. J Neuroendocrinol. 2023;35:e13347.","journal-title":"J Neuroendocrinol"},{"key":"3567_CR82","unstructured":"Wu D Efficacy and safety of BN101 in subjects with chronic graft versus host disease. BioNova Pharmaceuticals. NCT04930562. [Cited 17, January 2024], Database: ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04930562. 2021."},{"key":"3567_CR83","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cmet.2005.06.011","volume":"2","author":"N Furukawa","year":"2005","unstructured":"Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, et al. Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab. 2005;2:119\u201329.","journal-title":"Cell Metab"},{"key":"3567_CR84","doi-asserted-by":"publisher","first-page":"11776","DOI":"10.1074\/jbc.C900014200","volume":"284","author":"DH Lee","year":"2009","unstructured":"Lee DH, Shi J, Jeoung NH, Kim MS, Zabolotny JM, Lee SW, et al. Targeted disruption of ROCK1 causes insulin resistance in vivo. J Biol Chem. 2009;284:11776\u201380.","journal-title":"J Biol Chem"},{"key":"3567_CR85","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1002\/jcp.26278","volume":"233","author":"VR Munoz","year":"2018","unstructured":"Munoz VR, Gaspar RC, Kuga GK, da Rocha AL, Crisol BM, Botezelli JD, et al. Exercise increases Rho-kinase activity and insulin signaling in skeletal muscle. J Cell Physiol. 2018;233:4791\u20134800.","journal-title":"J Cell Physiol"},{"key":"3567_CR86","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/j.gastro.2018.06.039","volume":"155","author":"N Petersen","year":"2018","unstructured":"Petersen N, Frimurer TM, Terndrup Pedersen M, Egerod KL, Wewer Albrechtsen NJ, Holst JJ, et al. Inhibiting RHOA signaling in mice increases glucose tolerance and numbers of enteroendocrine and other secretory cells in the intestine. Gastroenterology. 2018;155:1164\u201376 e1162.","journal-title":"Gastroenterology"},{"key":"3567_CR87","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.biopha.2018.07.060","volume":"106","author":"V Jahani","year":"2018","unstructured":"Jahani V, Kavousi A, Mehri S, Karimi G. Rho kinase, a potential target in the treatment of metabolic syndrome. Biomed Pharmacother. 2018;106:1024\u201330.","journal-title":"Biomed Pharmacother"},{"key":"3567_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101625","volume":"66","author":"BJ Sung","year":"2022","unstructured":"Sung BJ, Lim SB, Yang WM, Kim JH, Kulkarni RN, Kim YB, et al. ROCK1 regulates insulin secretion from beta-cells. Mol Metab. 2022;66:101625.","journal-title":"Mol Metab"},{"key":"3567_CR89","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.3390\/molecules26164747","volume":"26","author":"NNQ Tran","year":"2021","unstructured":"Tran NNQ, Chun KH. ROCK2-specific inhibitor KD025 suppresses adipocyte differentiation by inhibiting casein kinase 2. Molecules. 2021;26:4747.","journal-title":"Molecules"},{"key":"3567_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17809-w","volume":"7","author":"C Borgo","year":"2017","unstructured":"Borgo C, Milan G, Favaretto F, Stasi F, Fabris R, Salizzato V, et al. CK2 modulates adipocyte insulin-signaling and is up-regulated in human obesity. Sci Rep. 2017;7:17569.","journal-title":"Sci Rep"},{"key":"3567_CR91","unstructured":"belumosudil (Rx). Medscape 2022 [Cited]. Available from: https:\/\/reference.medscape.com\/drug\/rezurock-belumosudil-4000186."}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03567-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:02:09Z","timestamp":1783965729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03567-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3567"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03567-7","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded in part by Sumitomo Pharma. Fasudil hydrochloride was received from Asahi Kasei Pharma Corp.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures were conducted in accordance with institutional and national guidelines and regulations. The study was approved by the Institutional Animal Care and Use Committee of Nagoya University (M230121-003, M240152-004, and M250107-001). No human participants were involved in this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}